A Comparison of the Pharmacokinetics and Pharmacodynamics of Pregabalin and Gabapentin

被引:0
|
作者
Howard N. Bockbrader
David Wesche
Raymond Miller
Sunny Chapel
Nancy Janiczek
Paula Burger
机构
[1] Pfizer Global Research & Development,
[2] Pfizer Global Research & Development,undefined
来源
Clinical Pharmacokinetics | 2010年 / 49卷
关键词
Neuropathic Pain; Gabapentin; Pregabalin; Postherpetic Neuralgia; Pain Score Reduction;
D O I
暂无
中图分类号
学科分类号
摘要
Pregabalin and gabapentin share a similar mechanism of action, inhibiting calcium influx and subsequent release of excitatory neurotransmitters; however, the compounds differ in their pharmacokinetic and pharmacodynamic characteristics. Gabapentin is absorbed slowly after oral administration, with maximum plasma concentrations attained within 3–4 hours. Orally administered gabapentin exhibits saturable absorption — a nonlinear (zero-order) process — making its pharmacokinetics less predictable. Plasma concentrations of gabapentin do not increase proportionally with increasing dose. In contrast, orally administered pregabalin is absorbed more rapidly, with maximum plasma concentrations attained within 1 hour. Absorption is linear (first order), with plasma concentrations increasing proportionately with increasing dose. The absolute bioavailability of gabapentin drops from 60% to 33% as the dosage increases from 900 to 3600 mg/day, while the absolute bioavailability of pregabalin remains at <-90% irrespective ofthe dosage. Both drugs can be given without regard to meals. Neither drug binds to plasma proteins. Neither drug is metabolized by nor inhibits hepatic enzymes that are responsible for the metabolism of other drugs. Both drugs are excreted renally, with elimination half-lives of approximately 6 hours.
引用
收藏
页码:661 / 669
页数:8
相关论文
共 50 条
  • [21] Pregabalin/gabapentin abuse warning
    不详
    PROGRESS IN NEUROLOGY AND PSYCHIATRY, 2015, 19 (01) : 35 - 35
  • [22] Pregabalin and gabapentin for the treatment of sciatica
    Robertson, Kelvin
    Marshman, Laurence A. G.
    Plummer, David
    JOURNAL OF CLINICAL NEUROSCIENCE, 2016, 26 : 1 - 7
  • [23] Abuse and Misuse of Pregabalin and Gabapentin
    Kirk E. Evoy
    Megan D. Morrison
    Stephen R. Saklad
    Drugs, 2017, 77 : 403 - 426
  • [24] POPULATION PHARMACOKINETICS- PHARMACODYNAMICS OF GABAPENTIN AFTER ADMINISTRATION OF GABAPENTIN ENACARBIL TABLETS IN SUBJECTS WITH RESTLESS LEGS SYNDROME.
    Lal, R.
    Kshirsagar, S.
    Sukbuntherng, J.
    Navvab, Z.
    Lassauzet, M.
    Cundy, K. C.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 : S58 - S59
  • [25] The echinocandins: Comparison of their pharmacokinetics, pharmacodynamics and clinical applications
    Wagner, Claudia
    Graninger, Wolfgang
    Presterl, Elisabeth
    Joukhadar, Christian
    PHARMACOLOGY, 2006, 78 (04) : 161 - 177
  • [26] Direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban
    Frost, C.
    Song, Y.
    Barrett, Y. C.
    Wang, J.
    Li, T.
    LaCreta, F.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 569 - 570
  • [27] COMPARISON OF THE PHARMACOKINETICS AND PHARMACODYNAMICS OF PERINDOPRIL, CILAZAPRIL AND ENALAPRIL
    LOUIS, WJ
    CONWAY, EL
    KRUM, H
    WORKMAN, B
    DRUMMER, OH
    LAM, W
    PHILLIPS, P
    HOWES, LG
    JACKSON, B
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 1992, : 55 - 60
  • [28] Comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban in dogs
    Lynch, Alex M.
    Ruterbories, Laura K.
    Zhu, Yao
    Fialkiewicz, Frank
    Papich, Mark G.
    Brooks, Marjory B.
    Goggs, Robert
    JOURNAL OF VETERINARY INTERNAL MEDICINE, 2024, 38 (06) : 3242 - 3254
  • [29] A cost-effectiveness comparison of desipramine, gabapentin, and pregabalin for treating postherpetic neuralgia
    O'Connor, Alec B.
    Noyes, Katia
    Holloway, Robert G.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2007, 55 (08) : 1176 - 1184